



KEEPING KIDS IN TUNE

Fennec Pharmaceuticals Inc. is a speciality pharmaceutical company focused on the development of PEDMARK™ (a unique formulation of sodium thiosulfate) for the prevention of platinum-induced ototoxicity in pediatric patients. Cisplatin, a widely used platinum based chemotherapy agent, can cause irreversible and permanent hearing loss in children. Fennec has completed two pediatric Phase III studies to evaluate the reduction in ototoxicity and impact on survival.

INVESTMENT HIGHLIGHTS

US Orphan Drug Designation

(7.5 years market exclusivity).

- Potential for 10 years of European market exclusivity for pediatric use.

Completed enrollment

of two Phase 3 trials.

Proof of concept COG Phase 3 trial achieved primary endpoint for hearing

- Achieved primary efficacy endpoint of hearing loss protection, $p=0.004$.

SIOPEL 6 Phase 3 trial showed that the addition of sodium thiosulfate significantly reduces the incidence of cisplatin-induced hearing loss without any evidence of tumor protection.

- Among the 99 evaluable patients, hearing loss occurred in 30/45=67% under Cisplatin Arm and in 20/54=37% under Cis+STS Arm, corresponding to a relative risk of 0.56, $p=0.0033$.

- STS safe to treat SR-HB with six cycles cisplatin monotherapy with the delayed addition of STS (ASCO/SIOP 2016).

Significant unmet medical need with no approved treatment on market or in development.

Continuing discussions with US & European regulators in 2017; NDA/MAA submission 2018.

ABOUT US

NASDAQ	FENC
TSX	FRX
Recent Market Price	USD \$9.98
Shares Outstanding	15.9
Cash*	USD \$9.7M
Cash Runway	Q4 2018
Debt	\$0

* September 30, 2017

INSTITUTIONAL OWNERSHIP

Southpoint Capital - 25%
Leadiant Bio (Sigma Tau) – 19%
Manchester Management - 13%
683 Capital – 6%

Varana Capital - 5%
venBio Select Advisor - 5%
Sonic Fund - 2%
Acuta Capital - 2%

MARKET OPPORTUNITY

In the U.S. and Europe it is estimated that over 7,000 children are diagnosed each year with cancers that may receive platinum based chemotherapy. These tumors have generally good prognosis with survival rates of greater than 80%, further emphasizing the importance of quality of life after treatment is completed. The incidence of hearing loss in these children is approximately 60%, with many requiring lifelong hearing aids and technically difficult and sub-optimal cochlear (inner ear) implants. Infants and young children at critical stages of development with even mild hearing loss lack speech language development and literacy, while older children and adolescents

lack social-emotional development and educational achievement. There is currently no established preventive agent for ototoxicity on the market.

STS has been studied by cooperative groups in two Phase 3 clinical studies of survival and reduction of ototoxicity, The Clinical Oncology Group Protocol ACCL0431 and SIOPEL 6. Both studies are closed to recruitment. The COG ACCL0431 protocol enrolled one of five childhood cancers typically treated with intensive cisplatin therapy for localized and disseminated disease, including newly diagnosed hepatoblastoma, germ cell tumor, osteosarcoma, neuroblastoma, and medulloblastoma. SIOPEL 6 enrolled only hepatoblastoma patients with localized tumors.

BOARD OF DIRECTORS

DR. KHALID ISLAM | *Chairman of Board*
 Chairman & CEO at Gentium S.p.A. Sold to Jazz Pharma for \$1 billion.

DR. MARCO BRUGHERA | *Director, CEO & Global Head of Leadiant BioSciences Ltd.*
 Previously successfully outlicensed Defibrotide US rights to Jazz Pharma to Baxalta for \$1 billion.

ROSTY RAYKOV | *CEO & Director*

ADRIAN HAIGH | *Director.* Currently SVP & GM at PTC Therapeutics. Previously COO at Gentium S.p.A. Sold to Jazz Pharma for \$1 billion.

CHRIS RALLIS | *Director.* Previously President & COO of Triangle Pharmaceuticals. Sold to Gilead for \$500 million.